Resumen

PINERO, Eva et al. Beneficio del agonista gaba B (Baclofen) sobre los hallazgos clínicos y endoscópicos en pacientes con esofagitis por enfermedad de reflujo gastroesofágico. Gen [online]. 2007, vol.61, n.3, pp.188-191. ISSN 0016-3503.

This study was made with the purpose of verifying the benefit of agonist GABA B (Baclofen) on the clinical and endoscopic findings in patients with esophagitis due to gastroesophageal reflux disease (GERD). In attention to this, specific objectives were established. 1-To evaluate the effect of agonist GABA-B on the symptoms of patients with GERD, we used the pain scale from 0 to 10. 2- To evaluate the endoscopic findings of GERD esophagitis in patients receiving 40mg daily of Baclofen, using Los Angeles classification. 3- To evaluate the tolerance of the drug (BACLOFEN). 4- To evaluate if the effect is different with respect to age, sex, time of evolution of the disease. The study started with a detailed revision of the physiology, physiopathology of the transitory relaxations of the inferior esophageal sphincter and the mechanism of action of Baclofen (GABA-B). The study corresponds to a longitudinal, prospective and experimental investigation. The population included were 16 patients who attended the gastroenterology unit of the C.H.E.T presenting GERD symptoms, but we only included 10 patients who fulfilled the criteria established for inclusion in the study and completed the month of treatment. A medical history, pre and post treatment endoscopic studies and laboratory were performed, and finally we determined the growth hormone concentration. The results were represented in graphics and charts and then they were interpreted. The benefits of Baclofen in GERD were demonstrated and final conclusions and recommendations were presented.

Palabras clave : GERD; transitory Relaxations of the IES.